Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

The human preclinical model at UAB provides important knowledge before a Phase I clinical trial can begin for living human recipients. Decades of work by researchers across the world preceded UAB’s first clinical-grade pig kidney xenotransplant.

A detailed mechanistic study unravels how the bacterial endotoxin LPS prevents or promotes allergic disease.

Disruption of Blimp1 in regulatory T cells remodels the tumor microenvironment and augments the response to immunotherapy.

Research in animal models shows better formation of the fistulas, which are a lifeline for kidney failure patients as the connection site to dialysis machines.

At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.

Basic and translational research in this field aims to repair heart injury and prevent the heart failure that often follows a heart attack.

Bacteria use molecular machines to move proteins, including toxins, across cell membranes. M. tuberculosis, which kills more than 1 million people a year, uses the ESX-4 type VII secretion system to transports its potent exotoxin.
Preclinical experiments show how to identify non-responding tumors and improve their response to immunotherapy, using two investigational new drugs that are permitted for human use. Physicians could immediately start investigational research in patients to test the effectiveness of this personalized approach.

The latest grant for Andrea Cherrington, M.D., is $21.7 million over five years from the National Institute on Minority Health and Health Disparities to improve chronic disease outcomes for Black Americans in the Deep South.

The life sciences fund will focus on development of early-stage UAB technologies and startup companies.
Page 1 of 40